The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.

The offering will support a trio of medicines in or nearing clinical testing, as well as earlier research into RNAi ...

The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an ...

Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies the company — now known as Lakefront Biotherapeutics — divested in a strategic overhaul.

A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one ...

The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.

Part of a wave of young biotechs employing AI to accelerate research, the company claimed in regulatory filings that its approach has the potential to “disrupt legacy drug discovery paradigms.” ...

In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein ...

Wall Street analysts believe Verastem’s drug to now be “competitive” in what’s quickly become one of the most active and ...

Prosecutors say the company filled unnecessary prescriptions that fueled the opioid epidemic. A spokesperson for CVS said the company admitted to no wrongdoing and “strongly disagreed” with the case’s ...

A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is ...

Yet one factor remains consistently underestimated: physical connectivity or fluid management. The tubing, connectors, ...